Your browser doesn't support javascript.
loading
Missed rifampicin and isoniazid resistance by commercial molecular assays.
Richards, L; Ismail, F; Nel, J; Omar, S V.
Afiliação
  • Richards L; Division of Infectious Diseases, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. lauren.richards@wits.ac.za.
  • Ismail F; Centre for Tuberculosis, National Institute for Communicable Diseases, Division of the National Health Laboratory Service, Johannesburg, South Africa; Department of Medical Microbiology, School of Medicine, University of Pretoria, South Africa. FarzanaI@nicd.ac.za.
  • Nel J; Division of Infectious Diseases, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. jeremy.nel@wits.ac.za.
  • Omar SV; Centre for Tuberculosis, National Institute for Communicable Diseases, Division of the National Health Laboratory Services, Johannesburg, South Africa, Department of Medical Microbiology, University of Pretoria, Pretoria, South Africa and Department of Molecular Medicine, University of Witwatersrand
S Afr Med J ; 114(7): e1779, 2024 Jul 01.
Article em En | MEDLINE | ID: mdl-39041520
ABSTRACT
Drug-resistant tuberculosis (TB) has poor outcomes unless resistance is detected early, ideally by commercially available molecular tests. We present a case of occult multidrug-resistant TB where both rifampicin and isoniazid resistance were missed by molecular testing and were only identified by phenotypic testing.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Rifampina / Tuberculose Resistente a Múltiplos Medicamentos / Isoniazida / Mycobacterium tuberculosis / Antituberculosos Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Rifampina / Tuberculose Resistente a Múltiplos Medicamentos / Isoniazida / Mycobacterium tuberculosis / Antituberculosos Idioma: En Ano de publicação: 2024 Tipo de documento: Article